<DOC>
	<DOCNO>NCT01896726</DOCNO>
	<brief_summary>The main purpose study find body absorbs break common birth control pill call Microgynon give study drug call baricitinib . Safety body 's ability tolerate baricitinib Microgynon also study . The study last approximately 6 week participant .</brief_summary>
	<brief_title>A Study Baricitinib Birth Control Pills Healthy Females</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<criteria>Premenopausal females currently successfully use nonhormonal method contraception include tubular ligation , cervical vault cap , diaphragm , non hormonal coil spermicide require addition use second approve method contraception duration study ( i.e. , male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence [ participant report abstinence become sexually active study must agree use additional barrier method contraception ] ) . The pregnancy test result must negative screen checkin visit . Participants must regular menstrual cycle approximately 28 day duration least 4 previous cycle prior screen Postmenopausal female , woman childbearing potential due surgical sterilization ( least 3 month surgical hysterectomy , least 3 month bilateral oophorectomy bilateral tubal occlusion without hysterectomy ) confirm medical history , menopause . Menopausal woman include woman spontaneous amenorrhea least 12 month amenorrhea induce medical condition anorexia nervosa and/or take medication time amenorrhea ( e.g. , oral contraceptive [ OCs ] , hormone , gonadotropin release hormone , antiestrogens , selective estrogen receptor modulators , chemotherapy ) . Postmenopausal status confirm serum folliclestimulating hormone level screen great 40 international unit per liter ( IU/L ) Have body mass index 18 30 kilogram per square meter ( kg/m^2 ) , inclusive Have positive pregnancy test lactating Are currently enrol , complete discontinue within last 90 day clinical trial involve study drug ; concurrently enrol type medical research judge scientifically medically compatible study Are persons previously complete withdrawn study study investigate baricitinib , previously receive study drug Have know allergy baricitinib Microgynon ( contain ethinyl estradiol levonorgestrel ) relate compound Have use intend use drug substance know inducer inhibitor cytochrome P450 3A ( eg , St. John 's wort , rifampin , ketoconazole ) within 30 day prior first dose Have take OCs within 3 month , implant contraceptive within 6 month , injectable contraceptive within 12 month , topical control delivery contraceptive ( patch ) hormonal coil within 3 month prior study Have history presence thromboembolic disease , recurrent jaundice , acute chronic liver disease , hormonallyinduced migraine , undiagnosed vaginal bleeding , significant hyperlipidemia , mammary , endometrial , hepatic carcinoma ( know suspect ) Smokes 10 cigarette per day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>